Key Takeaways on the Management of Clear-Cell RCC

News
Video

In closing, experts share clinical pearls on open communication with patients, dose reduction strategies, and the relevance of treatment holidays for improving quality of life in patients with renal cell carcinoma.

Summary:

In closing the discussion on advanced renal cell carcinoma (RCC), the experts offer valuable clinical practice pearls. Emphasizing the importance of clear communication, the need to assess patients’ understanding of their illness, treatment goals, and values is underscored. The discussion acknowledges that best supportive care is a viable option at various points in the cancer journey, and it’s crucial to ensure patients comprehend their situation for informed decision-making.

The predominant use of VEGF receptor tyrosine kinase inhibitors (TKIs) in RCC is highlighted, with an emphasis on managing their associated toxicities. Dose modification is deemed a significant strategy often underutilized, emphasizing that many patients fare well on reduced VEGF-TKI doses, enhancing their quality of life and prolonging therapy duration. The experts stress that dose reduction should be a primary strategy for optimizing the benefits of these agents, emphasizing the finite nature of available therapies. A notable mention is made of the STAR trial in RCC, which demonstrated that patients on TKIs with treatment holidays had comparable overall survival to those on continuous dosing. This finding supports the idea that breaks from TKIs, especially for patients experiencing adverse effects, are not detrimental to overall survival, and such breaks can significantly improve patients’ quality of life, allowing them to attend important life events.

The discussion concludes by recognizing the dual role of these drugs: to control cancer and help patients feel well, enabling them to participate in significant life events. The experts express gratitude for the engagement in the lively discussion on RCC, emphasizing its informative and beneficial nature for clinical practice.

Summary is AI-generated and reviewed by Cancer Network editorial staff.

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content